Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.210 -0.190 (-2.02%)

Streaming Delayed Price Updated: 11:12 AM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Prothena Announces up to $100 Million Share Repurchase Plan

February 27, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance ↗

February 19, 2026

Via Chartmill

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

February 19, 2026

From Prothena Corporation plc

Via Business Wire

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

February 12, 2026

From Prothena Corporation plc

Via Business Wire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

9 Analysts Assess Prothena Corp: What You Need To Know ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

A Glimpse of Prothena Corp's Earnings Potential ↗

August 01, 2025

Via Benzinga

Prothena Announces Board of Directors Update

December 12, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

November 19, 2025

From Prothena Corporation plc

Via Business Wire

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Via Benzinga

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

November 11, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗

November 06, 2025

Prothena reports Q3 2025 earnings, provides updates on its neurodegenerative disease pipeline, and reaffirms strong cash position.

Via Chartmill

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Third Quarter 2025 Financial Results on November 6

October 30, 2025

From Prothena Corporation plc

Via Business Wire

Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗

October 07, 2025

Via Benzinga

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

October 01, 2025

From Prothena Corporation plc

Via Business Wire

Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 02, 2025

Via Benzinga

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗

August 29, 2025

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.

Via Benzinga

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

August 28, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗

August 28, 2025

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

Via Benzinga

What 4 Analyst Ratings Have To Say About Prothena Corp ↗

August 28, 2025

Via Benzinga

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

August 27, 2025

From Prothena Corporation plc

Via Business Wire

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗

August 06, 2025

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Via Stocktwits

Topics Earnings

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

August 06, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Q2 Revenue Drops 97% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

August 04, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Second Quarter 2025 Financial Results on August 4

July 28, 2025

From Prothena Corporation plc

Via Business Wire

8 Analysts Assess Prothena Corp: What You Need To Know ↗

June 20, 2025

Via Benzinga

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast ↗

June 20, 2025

The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline.

Via Stocktwits

Topics Workforce

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.